SWOG clinical trial number
SWOG-8005

Evaluation of Dihydroxyanthracenedione (DHAD) in Refractory Malignant Lymphomas

Closed
Phase
Abbreviated Title
Evaluation of Dihydroxyanthracenedione (DHAD) in Refractory Malignant Lymphomas
Activated
07/02/1980
Closed
05/10/1982

Research committees

Lymphoma

Publication Information Expand/Collapse

1984

Mitoxantrone in refractory NonHodgkin's lymphoma: A Southwest Oncology Group study

CA Coltman Jr;TM Coltman;SP Balcerzak;FS Morrison;DD Von Hoff Semin Oncol 11(3 Suppl 1):50-53

Mitoxantrone in refractory non-Hodgkin's lymphoma

CA Coltman Jr;TM Coltman;SP Balcerzak;FS Morrison;DD Von Hoff 2nd International Conference on Malignant Lymphoma (Swiss League Against Cancer and Swiss Group for Clinical Cancer Research Lugano Switzerland June 13-16 1984) 98

1983

Mitoxantrone hydrochloride (NSC-301739) in lymphoma. A Southwest Oncology Group study

CA Coltman Jr;TM McDaniel;SP Balcerzak;FS Morrison;DD Von Hoff Investigational New Drugs 1:065-070

Mitoxantrone hydrochloride in lymphoma

CA Coltman Jr;TM McDaniel;SP Balcerzak;FS Morrison;DD Von Hoff In: 13th International Congress of Chemotherapy (Vienna, August 28-Sepember 2, 1983). KH Spitzy, K Karrer, eds. Symposium Mitoxantrone 212:52-55

Mitoxantrone hydrochloride in lymphoma

CA Coltman Jr;TM McDaniel;SP Balcerzak;FS Morrison;DD Von Hoff Cancer Treat Rev 10(Suppl B):73-76

Mitoxantrone hydrochloride in hematologic malignancies: Southwest Oncology Group Phase II studies.

CA Coltman Jr;JH Saiki;FJ Panettiere;SP Balcerzak;RL Stephens;FS Morrison;DO Dixon;DD Von Hoff In: 3rd NCI-EORTC Symposium on New Drugs in Cancer Therapy (Brussels, October 15-17, 1981) M Rozencweig, DD Von Hoff, MJ Staquet, eds. New Anticancer Drugs: Mitoxantrone and Bisantrene. New York: Raven Press 115-124.

1981

Mitoxantrone Hydrochloride (NSC-30179) in hematologic malignancies

CA Coltman Jr;JH Saiki;FJ Panettiere;SP Balcerzak;RL Stephens;FS Morrison;DO Dixon;DD Von Hoff 3rd NCI-EORTC Symposium on New Drugs in Cancer Therapy (Brussels)

Other Clinical Trials

SWOG Clinical Trial Number
S2308

Randomized Phase III Study of Mosunetuzumab vs. Rituximab for Low Tumor Burden Follicular Lymphoma
Research Committee(s)
Lymphoma
Activated
08/01/2024
Accrual
1%
Open
Phase
SWOG Clinical Trial Number
S2207

Randomized Phase II Study of the Addition of Targeted Therapeutic Agents to Tafasitamab-Based Therapy in Non-Transplant-Eligible Patients with Relapse/Refractory Large B-Cell Lymphoma
Research Committee(s)
Lymphoma
Activated
06/30/2023
Accrual
12%
Open
Phase
SWOG Clinical Trial Number
CTSU/AHOD2131

A Randomized Phase 3 Interim Response Adapted Trial Comparing Standard Therapy with Immuno-oncology Therapy for Children and Adults with Newly Diagnosed Stage I and II Classic Hodgkin Lymphoma
Research Committee(s)
Lymphoma
Immunomolecular Therapeutics
Activated
04/28/2023
Open
Phase